Neisvac-C

Neisseria meningitidis group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid, the active ingredient in Neisvac-C, is a conjugate vaccine presented as a vaccine for intramuscular use. It is used to prevent invasive disease caused by Neisseria meningitidis serogroup C in at‑risk populations. GNH USA supplies Neisvac-C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Neisvac-C is a conjugate vaccine that targets meningococcal serogroup C and helps prevent serious invasive infections. - Invasive disease caused by Neisseria meningitidis serogroup C: provides active immunization to reduce the risk of meningitis, septicemia, and related complications. - Outbreak control in high‑risk settings: contributes to herd immunity and limits spread of serogroup C during community outbreaks.

Neisvac-C is generally well tolerated, but injection‑related reactions and rare severe events can occur.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache: mild to moderate headache post‑vaccination. - Fatigue: temporary tiredness. - Myalgia: muscle aches near the injection area.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurologic disorder with muscle weakness. - Seizures: uncommon convulsive episodes. - Severe hypotension: marked drop in blood pressure. - Neurologic events: rare encephalopathy or meningitis‑like symptoms. - Persistent high fever: prolonged febrile response beyond 48 hours.

Before administering Neisvac-C, consider the following precautions to ensure safe use. - Allergy assessment: verify no known hypersensitivity to vaccine components or tetanus toxoid. - Pregnancy: consult a healthcare professional; limited safety data are available. - Immunocompromised patients: vaccine may elicit a reduced immune response. - Concomitant vaccines: follow recommended intervals when co‑administering other immunizations. - Age suitability: ensure the patient falls within the approved age range for the vaccine. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac-C may interact with other medical products; awareness of potential interactions helps maintain vaccine efficacy and safety.

Major Interactions (Avoid): - Live vaccines: avoid co‑administration within 4 weeks to prevent interference. - Immunoglobulin therapy: may diminish vaccine response if given within 3 months. - Blood products: can affect immunogenicity if administered within 4 weeks.

Moderate Interactions (Monitor Closely): - Antipyretics: may mask post‑vaccination fever, reducing clinical observation. - Immunosuppressants: monitor antibody response as effectiveness may be reduced. - Allergy medications: may alter the severity of local or systemic reactions.